Skip to content

Transcutaneous Electrical Phrenic Nerve Stimulation for Reducing Mechanical Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial?

Transcutaneous Electrical Phrenic Nerve Stimulation for Reducing Mechanical Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106948
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cerebral infarction patients receiving mechanical ventilation

Interventions

Control group:sham stimulation
Intervention group:?Transcutaneous Electrical Phrenic Nerve Stimulation

Sponsors

Xuanwu Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years old; 2.No gender restrictions; 3.Patient diagnosed with acute cerebral infarction (within 30 days of onset) through cranial CT or MRI; 4.Duration of mechanical ventilation >= 24 hours; 5.The patient or their legal guardian agrees to participate in the study and signs an informed consent form;

Exclusion criteria

Exclusion criteria: 1.There are other significant conditions that affect diaphragm function, such as severe malnutrition, irreversible respiratory pump failure caused by medullary or cervical cord injury, and irreversible damage to the phrenic nerve; 2.Significant agitation cannot be combined with ?transcutaneous electrical phrenic nerve stimulation; 3.Severe skin damage or infection at the electrode placement site; 4.Previous presence of severe lung disease (such as severe COPD, interstitial lung disease, pulmonary embolism, etc.), severe heart failure (NYHA Class IV); 5.Sepsis or shock requiring high-dose vasopressors; 6.The terminal state of the disease or expected survival period does not exceed 7 days; 7.Pacemaker implantation; 8.Pregnant or lactating women; 9.Patients whose family members express their willingness to withdraw for treatment;

Design outcomes

Primary

MeasureTime frame
Mecanical ventilation duration;

Secondary

MeasureTime frame
Successful weaning rate;mRS at 90 day;

Countries

China

Contacts

Public ContactLinlin Fan

Xuanwu Hospital Capital Medical University

fanlinlin@xwhosp.org+86 10 8319 8640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026